State-of-the-art patient-derived cancer models – driving new insights and treatments in cancer

Pancreatic ductal adenocarcinoma (PDAC) and oesophageal cancers are devastating diseases with very limited treatment options and an extremely poor prognosis. Identifying novel biological vulnerabilities is therefore critical to develop more effective therapies. In this seminar, two experts discussed using murine and human cancer organoids to identify and validate therapeutic targets.